All In Biotech

Drug Trial Radar · NCT05478109

A Clinical Trial of XZP-3287 for Material Balance

the Material Balance and Biotransformation Study of [14C] XZP-3287 in Healthy Chinese Male Subjects

Last checked: Nov 20, 2026Latest source record: Jul 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

10

Planned (sponsor's estimate)

Start

Aug 2, 2022

Primary completion

Jan 4, 2023

Study completion Jan 4, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of \[14C\] XZP-3287

Conditions

  • Healthy Male Subjects

Interventions

  • [14C]XZP-3287Drug

    360 mg suspension containing 50µCi of \[14C\] XZP-3287

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK data for 14C-XZP-3287: CmaxTime frame: up to 15 days
  2. PK data for 14C-XZP-3287: AUClastTime frame: up to 15 days
  3. PK data for 14C-XZP-3287: AUCinfTime frame: up to 15 days
  4. PK data for 14C-XZP-3287: TmaxTime frame: up to 15 days
  5. Quantitative analysis of cumulative excretion and excretion rate in excreta (urine and faeces)Time frame: up to 15 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Gaobo Boren Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.